98%
921
2 minutes
20
Aims: In an era of evolving diagnostic possibilities, existing diagnostic systems are not fully sufficient to promptly recognize patients with early-stage hypertrophic cardiomyopathy (HCM) without symptomatic and instrumental features. Considering the sudden death of HCM, developing a novel diagnostic model to clarify the patients with early-stage HCM and the immunological characteristics can avoid misdiagnosis and attenuate disease progression.
Methods And Results: Three hundred eighty-five samples from four independent cohorts were systematically retrieved. The weighted gene co-expression network analysis, differential expression analysis (|log2(foldchange)| > 0.5 and adjusted P < 0.05), and protein-protein interaction network were sequentially performed to identify HCM-related hub genes. With a machine learning algorithm, the least absolute shrinkage and selection operator regression algorithm, a stable diagnostic model was developed. The immune-cell infiltration and biological functions of HCM were also explored to characterize its underlying pathogenic mechanisms and the immune signature. Two key modules were screened based on weighted gene co-expression network analysis. Pathogenic mechanisms relevant to extracellular matrix and immune pathways have been discovered. Twenty-seven co-regulated genes were recognized as HCM-related hub genes. Based on the least absolute shrinkage and selection operator algorithm, a stable HCM diagnostic model was constructed, which was further validated in the remaining three cohorts (n = 385). Considering the tight association between HCM and immune-related functions, we assessed the infiltrating abundance of various immune cells and stromal cells based on the xCell algorithm, and certain immune cells were significantly different between high-risk and low-risk groups.
Conclusions: Our study revealed a number of hub genes and novel pathways to provide potential targets for the treatment of HCM. A stable model was developed, providing an efficient tool for the diagnosis of HCM.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287386 | PMC |
http://dx.doi.org/10.1002/ehf2.14762 | DOI Listing |
J Cardiovasc Pharmacol
September 2025
Graduate School of Cardiology, Bengbu Medical University, Bengbu 233000, Anhui, China.
Chronic stress-induced cardiac hypertrophy remains a critical precursor to heart failure, with current therapies limited by incomplete mechanistic targeting. Cyclin-dependent kinases (CDKs), pivotal regulators of cell cycle and stress signaling, are emerging therapeutic targets in cardiovascular pathologies. Using bioinformatics analysis of human hypertrophic cardiomyopathy datasets (GSE5500, GSE136308) and a murine transverse aortic constriction (TAC) model, we investigated the therapeutic effects of the CDK inhibitor R547 (10 mg/kg, intraperitoneal every 3 days) on pressure overload-induced cardiac remodeling.
View Article and Find Full Text PDFJTCVS Open
August 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn.
Background: Proper risk stratification tools for patients with obstructive hypertrophic cardiomyopathy (oHCM) undergoing septal myectomy are lacking. Our objective was to assess the predictive value of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) on perioperative outcomes and late survival in patients with oHCM undergoing transaortic septal myectomy.
Methods: Between 2008 and 2021, 834 patients with preoperative NT-proBNP measurements underwent septal myectomy.
Heart Rhythm
September 2025
Tufts Medicine CardioVascular Center, Division of Cardiology, Boston, MA.
Int J Cardiol
September 2025
Department of Demography and Geodemography, Faculty of Science, Charles University, Prague, Czech Republic.
Background: Alcohol septal ablation (ASA) is an established therapy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) in patients unresponsive to medical treatment. However, comprehensive assessment of ASA outcomes remains challenging. This study aimed to evaluate the impact of institutional experience and patient characteristics on achieving complete clinical and haemodynamic response (CCHR), a novel composite outcome integrating long-term symptomatic, haemodynamic, safety, and major clinical endpoints, including survival and resuscitation.
View Article and Find Full Text PDFInt J Cardiol
September 2025
Division of Non-Invasive Cardiology, Cardiology Centre, Department of Medicine, University of Szeged, Hungary. Electronic address:
Background: Real-world data on the efficacy of mavacamten, indicated for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), are relatively scarce, particularly in patients with extreme left ventricular outflow tract (LVOT) gradients and concerning its short-term effects.
Patients/methods: We investigated a cohort of twenty-five oHCM patients [15 men (60 %), mean age: 55 ± 11 years], with a resting or provoked LVOT gradient of >100 mmHg, receiving mavacamten treatment. Patients underwent a complete standard and 2D-speckle tracking echocardiographic examination after one week (W1) of treatment initiation and at subsequent four-week intervals.